Affimed NV Faces Insolvency and Nasdaq Delisting

Affimed NV, a clinical-stage biopharmaceutical company specializing in targeted cancer immuno-oncology therapies, has recently faced significant financial challenges. The company, which operates globally in the health care sector with a focus on biotechnology, announced on May 13, 2025, that it has filed for insolvency proceedings with the local court of Mannheim, Germany. This development comes after unsuccessful efforts to secure sufficient capital to continue operations for Affimed N.V. and its subsidiaries, Affimed GmbH and Affimed Inc.

Following the insolvency filing, Affimed’s shares experienced a sharp decline. The company’s stock price, which was already at a low of €0.89 as of January 29, 2025, further plummeted. This financial distress led to a series of downgrades and negative ratings from financial analysts. On May 13, 2025, Leerink cut Affimed’s stock target to €0.39 and downgraded its rating. Additionally, Cantor Fitzgerald also reduced its stock rating on the same day, citing the insolvency news.

The financial turmoil has resulted in Affimed’s delisting from the Nasdaq stock exchange. On May 14, 2025, multiple sources, including Seeking Alpha and Investing.com, reported that Affimed would be delisted from Nasdaq following its insolvency filing. Affimed N.V. confirmed this development by announcing the receipt of a Nasdaq delisting notice on the same day.

As of May 1, 2025, Affimed’s close price was €0.972, with a market capitalization of €13,440,536. The company, which was listed on the Nasdaq stock exchange since its IPO on September 12, 2014, is now primarily traded on the Frankfurt Stock Exchange. The insolvency proceedings and subsequent delisting mark a significant downturn for Affimed, which had previously reached a 52-week high of €7 on June 2, 2024.

The company’s management has determined that despite ongoing fundraising efforts, they were unable to secure the necessary capital to sustain operations, leading to the current financial predicament. Affimed’s focus on developing targeted cancer immuno-oncology therapies remains a critical aspect of its business, but the financial challenges pose significant hurdles for its future endeavors.